PDF icon Download PDF
Am J Perinatol 2024; 41(S 01): e400-e405
DOI: 10.1055/a-1884-1221
Original Article

A Trial of Labor after Cesarean Section with a Macrosomic Neonate. Is It Safe?

Miriam Lopian 
1   Department of Obstetrics and Gynecology, Mayanei Hayeshua Medical Center, Bnei Brak, Israel
2   Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Lior Kashani-Ligumski
1   Department of Obstetrics and Gynecology, Mayanei Hayeshua Medical Center, Bnei Brak, Israel
2   Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Ronnie Cohen
1   Department of Obstetrics and Gynecology, Mayanei Hayeshua Medical Center, Bnei Brak, Israel
2   Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
,
Jacky Herzlich
2   Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
4   Department of Neonatology, Lis Hospital for Women, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
,
Sharon Perlman
2   Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
5   Prenatal Ultrasound Unit The Helen Schneider Hospital for Women, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel
› Author Affiliations
Funding None.
› Further Information
Also available ateRefHebammen
  Permissions and Reprints
Preview

Abstract

Objective This study aimed to determine whether a trial of labor after cesarean section (TOLAC) with a macrosomic neonate is associated with adverse outcomes.

Study Design A retrospective cohort study was conducted in a population motivated for TOLAC. Women attempting TOLAC with a neonatal birth weight >4,000 g were compared with women attempting TOLAC with neonatal birth weights between 3,500 and 4,000 g. The primary outcome was TOLAC success. Secondary outcomes included mode of delivery, uterine rupture, postpartum hemorrhage (PPH), shoulder dystocia, obstetric anal sphincter injury (OASI), Apgar's score <7 at 5 minutes, and umbilical artery pH <7.1. Data were analyzed using Fisher's exact test and Chi‐square test.

Results Overall, 375 women who underwent TOLAC with a neonate weighing >4,000 g comprised the study group. One thousand seven hundred and eighty-three women attempting TOLAC with a neonate weighing 3,500 to 4,000 g comprised the control group. There were no clinically significant differences between the groups for maternal age, gestational age, parity, and vaginal birth after cesarean (VBAC) rate. There were no significant differences in the rates of successful TOLAC (94 vs. 92.3%, p = 0.2, odds ratio [OR] = 0.8, 95% confidence interval [CI]: 0.5, 1.2), operative vaginal delivery (7.4 vs. 5.3%, p = 0.18, OR = 0.7, 95% CI: 0.4, 1.1), uterine rupture (0.4 vs. 0%, p = 0.6), PPH (3.2 vs. 2.3%, p = 0.36, OR = 1.4, 95% CI: 0.7, 2.7), OASI (0.8 vs. 0.2%, p = 0.1, OR = 3.6, 95% CI: 0.8, 1.6), Apgar's score <7 at 5 minutes (0 vs. 0.4%, p = 0.37), and umbilical artery pH <7.1 (0.5 vs. 0.7%, p = 1.0, OR = 0.73, 95% CI: 0.2, 3.2). Women with a neonate weighing >4,000 g had a significantly increased risk of shoulder dystocia (4 vs. 0.4%, p < 0.05, OR = 9.2 95% CI: 3.9, 22)

Conclusion Women attempting TOLAC with a macrosomic neonate are not at increased risk for failed TOLAC, operative vaginal delivery, uterine rupture, PPH, or OASI but are at risk of shoulder dystocia. This information may aid in prenatal counseling for women considering TOLAC with a macrosomic fetus.

Key Points

  • TOLAC with fetal macrosomia does not increase the risk of uterine rupture.

  • TOLAC with fetal macrosomia is associated with high chances of VBAC.

  • TOLAC with fetal macrosomia is not associated with adverse neonatal outcomes.

Keywords

macrosomia - a trial of labor after cesarean - TOLAC - cesarean delivery

Ethical Approval

This study was conducted in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments. The local ethical committee approved the study. Since the study was retrospective, there was a waiver from informed consent by the local ethical committee.


Authors' Contributions

M.L.: project development, data collection, and first draft manuscript writing.


L.K.-L.: Project development, data collection, and review of the final version of the manuscript.


R.C.: data collection and review of the final version of the manuscript.


J.H.: data collection and review of the final version of the manuscript.


S.P.: project development, supervision, and first draft manuscript writing.




Publication History

Received: 08 January 2022

Accepted: 21 June 2022

Accepted Manuscript online:
24 June 2022

Article published online:
16 September 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA